MY173288A - Boswellia oil, its fractions and compositions for enhancing brain function - Google Patents

Boswellia oil, its fractions and compositions for enhancing brain function

Info

Publication number
MY173288A
MY173288A MYPI2012700603A MYPI2012700603A MY173288A MY 173288 A MY173288 A MY 173288A MY PI2012700603 A MYPI2012700603 A MY PI2012700603A MY PI2012700603 A MYPI2012700603 A MY PI2012700603A MY 173288 A MY173288 A MY 173288A
Authority
MY
Malaysia
Prior art keywords
boswellia
memory
fraction
fractions
compositions
Prior art date
Application number
MYPI2012700603A
Inventor
Ganga Raju Gokaraju
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Trimurtulu Golakoti
Kiran Bhupathiraju
Original Assignee
Laila Nutraceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutraceuticals filed Critical Laila Nutraceuticals
Publication of MY173288A publication Critical patent/MY173288A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A non-acidic extract/fraction selected from Boswellia low polar gum resin extract fraction (BLPRE), Boswellia volatile oil fraction (BVOIL) and Boswellia oil fraction (BOIL) derived from the gum resin of Boswellia species for improving mental condition/brain health; enhancing brain functions such as cognition, memory, learning, communication; for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases.
MYPI2012700603A 2010-03-15 2011-03-14 Boswellia oil, its fractions and compositions for enhancing brain function MY173288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN687CH2010 2010-03-15
PCT/IN2011/000170 WO2011114350A2 (en) 2010-03-15 2011-03-14 Boswellia oil, its fractions and compositions for enhancing brain function

Publications (1)

Publication Number Publication Date
MY173288A true MY173288A (en) 2020-01-13

Family

ID=54291846

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012700603A MY173288A (en) 2010-03-15 2011-03-14 Boswellia oil, its fractions and compositions for enhancing brain function

Country Status (7)

Country Link
CN (1) CN102811728A (en)
AU (2) AU2011228689A1 (en)
BR (1) BR112012022983A2 (en)
CA (1) CA2793045A1 (en)
MY (1) MY173288A (en)
SG (1) SG184006A1 (en)
WO (1) WO2011114350A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151840A2 (en) * 2010-05-30 2011-12-08 Laila Nutraceuticals Compositions comprising non-acidic boswellia oil fraction as a bio-enhancer for enhancing the bioavailability of biological agents
GB201111319D0 (en) 2011-07-04 2011-08-17 Univ Leuven Kath Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa
JP6985139B2 (en) * 2014-10-21 2021-12-22 アルピニア・ローダナム・インスティテュート・オブ・フィトファーマシューティカル・サイエンシーズ・アクチェンゲゼルシャフトAlpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag Extracts from Boswellia plants, as well as related products and uses
WO2016166565A1 (en) * 2015-04-13 2016-10-20 Ethnodyne Use of a withania extract for the treatment of alpha synucleinopathies
CN108853069A (en) * 2017-05-16 2018-11-23 四川省中医药科学院 Purposes of the tetrahydro curcumin in the drug or health care product that preparation improves memory
CN107349190B (en) * 2017-07-19 2021-04-23 广东工业大学 Application of arylturmerone
IT201900013707A1 (en) * 2019-08-01 2021-02-01 Cristalfarma S R L Food supplement, for use as an adjuvant, for the prevention of vascular dementia
EP4114204A4 (en) * 2020-03-03 2024-01-10 Laila Nutraceuticals Synergistic compositions for improving brain health
WO2021205083A2 (en) 2020-04-11 2021-10-14 Finindsutria Srl Composition for the prevention or treatment of covid-19
CN116370523A (en) * 2023-04-04 2023-07-04 昆明理工大学 Application of plant essential oil in preparation of antiepileptic drugs or health products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4444288A1 (en) * 1994-12-13 1996-06-20 Rainer Dr Med Etzel Use of frankincense to treat Alzheimer's disease
US20070248693A1 (en) * 2003-08-02 2007-10-25 Elizabeth Mazzio Nutraceutical composition and method of use for treatment / prevention of cancer
US7873730B2 (en) * 2003-11-10 2011-01-18 International Business Machines Corporation Method and system for collaborative computing environment access restriction and orphan data management
CN1583063B (en) * 2004-06-10 2012-03-28 山东齐都药业有限公司 Extraction of effective components from frankinscene and its preparation and use
WO2008036932A2 (en) * 2006-09-21 2008-03-27 Herbalscience Singapore Pte. Ltd. Compositions and methods comprising boswellia species

Also Published As

Publication number Publication date
AU2016201084A1 (en) 2016-03-17
WO2011114350A3 (en) 2011-11-10
SG184006A1 (en) 2012-10-30
WO2011114350A2 (en) 2011-09-22
CA2793045A1 (en) 2011-09-22
BR112012022983A2 (en) 2015-09-15
CN102811728A (en) 2012-12-05
AU2016201084B2 (en) 2017-10-19
AU2011228689A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
MY173288A (en) Boswellia oil, its fractions and compositions for enhancing brain function
CY1121136T1 (en) HERBAL EXTRACTS CONTAINING CANNABINOIDS AS NEUROPROSPERATIVE FACTORS
MX2017013562A (en) Microbiome regulators and related uses thereof.
MY159856A (en) Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
WO2010021693A3 (en) Mif modulators
WO2012020307A3 (en) Therapeutic uses of microvesicles and related micrornas
WO2011140202A3 (en) Mif modulators
WO2011090738A3 (en) Type ii raf kinase inhibitors
PH12013501074A1 (en) Compositions and methods for treatment of microbial disorders
WO2008052166A3 (en) Systems and methods for altering brain and body functions an treating conditions and diseases
MX2012004638A (en) Modulation of axon degeneration.
MX352661B (en) Novel benzopyran kinase modulators.
MX2013010343A (en) Compositions and methods for transplantation of colon microbiota.
NZ711771A (en) Compositions for treating or preventing or reducing the severity of clostridium difficile related diseases
WO2014149138A3 (en) Lice control composition and method
MY172372A (en) Compositions and methods for lowering triglycerides
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
WO2011048617A3 (en) Extracts, fractions and compositions comprising acetogenins and their applications
IN2014DN06792A (en)
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
WO2011082245A3 (en) Metalloenzyme inhibitor compounds
EP3581177A3 (en) Compositions comprising acidic extracts of mastic gum
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
WO2014126965A3 (en) Compositions and methods for treating pathological calcification and ossification